Molecular mechanisms and clinical applications of angiogenesis

Peter Carmeliet () and Rakesh K. Jain ()
Additional contact information
Peter Carmeliet: Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB
Rakesh K. Jain: Edwin L. Steele Laboratory for Tumor Biology, Massachusetts General Hospital and Harvard Medical School

Nature, 2011, vol. 473, issue 7347, 298-307

Abstract: Abstract Blood vessels deliver oxygen and nutrients to every part of the body, but also nourish diseases such as cancer. Over the past decade, our understanding of the molecular mechanisms of angiogenesis (blood vessel growth) has increased at an explosive rate and has led to the approval of anti-angiogenic drugs for cancer and eye diseases. So far, hundreds of thousands of patients have benefited from blockers of the angiogenic protein vascular endothelial growth factor, but limited efficacy and resistance remain outstanding problems. Recent preclinical and clinical studies have shown new molecular targets and principles, which may provide avenues for improving the therapeutic benefit from anti-angiogenic strategies.

Date: 2011
References: Add references at CitEc
Citations: View citations in EconPapers (11)

Downloads: (external link)
https://www.nature.com/articles/nature10144 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:473:y:2011:i:7347:d:10.1038_nature10144

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature10144

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().